ESSA Pharma Inc EPIX

Healthcare Biotechnology

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

NDAQ:EPIX - Post by User

ESSA Pharma Inc

Bullboard Posts

Post by SGordonon Oct 24, 2018 10:30pm

57 Views

Post# 28868854

News... Oct.22....

ESSA Appoints Otello Stampacchia, PH.D., of Omega Funds to Board of Directors

Canada NewsWire

HOUSTON and VANCOUVER, Oct. 22, 2018

HOUSTON and VANCOUVER, Oct. 22, 2018 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Otello Stampacchia, Ph.D., Founder and Managing Director of Omega Funds, a Boston-based biotech and medical device investment firm, to the Company's Board of Directors. Mr. Stampacchia was appointed pursuant to the terms of a nomination rights agreement between the Company and Omega Fund Management, LLC.